< Back to previous page
Researcher
Patrik Verstreken
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
- See also: Patrik Verstreken (Flanders Institute for Biotechnology)
Affiliations
- Research Group Molecular Neurobiology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Responsible
From1 Jan 2008 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Member
From1 Jan 2017 → Today - VIB-KU Leuven Center for Brain & Disease Research (Research Center)
Responsible
From1 Jan 2017 → Today - Verstreken Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 54
- The Role of Parkinsonism genes in synaptic autophagyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Tau-dependent synaptic remodeling in health and diseaseFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Translational Markers for Precision Medicine in Modifying Parkinson's DiseaseFrom1 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Investigating cell type specific defects in protein quality control across the genetic landscape of Parkinson’s diseaseFrom1 Oct 2022 → TodayFunding: FWO junior postdoctoral fellowship
- When size matters: a platform to study molecular interactions and multimerisationFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Dissecting the genetic interactions controlling α-Synuclein accumulation in Parkinson’s DiseaseFrom15 Mar 2022 → TodayFunding: FWO fellowships
- Analyzing the regulation of synaptic vesicle mobility by pre-synaptic liquid phase-separation in health and diseaseFrom7 Mar 2022 → TodayFunding: FWO fellowships
- Therapeutic targeting of pathogenic presynaptic Tau in human neurons in a chimeric Alzheimer’s Disease mouse modelFrom24 Jan 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Investigating cell type specific defects in protein quality control across the genetic landscape of Parkinson’s disease.From1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Resilience and vulnerability in the cellular phase of Alzheimer’s disease.From1 Oct 2021 → TodayFunding: BOF - Methusalem
Publications
21 - 30 of 146
- Molecule-to-Circuit Disease Mechanisms of a Synaptic SNAREopathy(2021)
Authors: Roman Praschberger, Julie Jacquemyn, Patrik Verstreken
Pages: 1 - 3 - A structure of substrate-bound Synaptojanin1 provides new insights in its mechanism and the effect of disease mutations(2020)
Authors: Patrik Verstreken
- Excess Lipin enzyme activity contributes to TOR1A recessive disease and DYT-TOR1A dystonia(2020)
Authors: Joyce Foroozandeh, Patrik Verstreken
Pages: 1746 - 1765 - Need for speed: Super-resolving the dynamic nanoclustering of syntaxin-1 at exocytic fusion sites(2020)
Authors: Adekunle Bademosi, Elsa Lauwers, Patrik Verstreken
- Second harmonic imaging of axonal microtubules and examining the impact of their molecular conformation on mitochondrial transport(2020)
Authors: Valérie Van Steenbergen, Pieter Vanden Berghe, Patrik Verstreken
- TBC1D24-TLDc-related epilepsy exercise-induced dystonia: rescue by antioxidants in a disease model(2019)
Authors: Patrik Verstreken
Pages: 2319 - 2335 - Mitochondria Re-set Epilepsy(2019)
Authors: Valerie Uytterhoeven, Natalie Kaempf, Patrik Verstreken
Pages: 907 - 910 - Purification of Soluble Recombinant Human Tau Protein from Bacteria Using Double-tag Affinity Purification(2018)
Authors: Patrik Verstreken
- Parkinson's disease: convergence on synaptic homeostasis(2018)
Authors: Sandra Fausia Soukup, Patrik Verstreken
- Hsp90 Mediates Membrane Deformation and Exosome Release(2018)
Authors: Elsa Lauwers, Yu-Chun Wang, Rodrigo Gallardo, Rob van der Kant, Emiel Michiels, Frederic Rousseau, Joost Schymkowitz, Patrik Verstreken
Pages: 689 - +
Patents
1 - 10 of 10
- Screening method for synaptogyrin-3 inhibitors (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Means and methods for treatment of early-onset parkinson's disease (Inventor)
- Means and methods for treatment of early-onset parkinson's disease (Inventor)
- Compounds for treatment of intractable epilepsy and doors syndrome (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Compounds for treatment of intractable epilepsy and doors syndrome (Inventor)
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease (Inventor)
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease (Inventor)